AstraZeneca’s Lung Portfolio Diverges: Two Phase III Wins, One Discontinuation
AstraZeneca disclosed three divergent Phase III lung-cancer outcomes on the same day. In SAFFRON, osimertinib plus savolitinib met progression-free-survival and overall-survival endpoints versus platinum chemotherapy after osimertinib progression in biomarker-selected EGFR-mutant, MET-driven non-small cell…
